查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
药物供给管理(PBM)的美国市场 - 市场规模，占有率，趋势分析:不同商业模式，各最终用途，市场区隔预测(2023年～2030年)
市场调查报告书
商品编码
1171136

药物供给管理(PBM)的美国市场 - 市场规模，占有率，趋势分析:不同商业模式，各最终用途，市场区隔预测(2023年～2030年)

U.S. Pharmacy Benefit Management Market Size, Share & Trends Analysis Report By Business Model (Standalone, Health Insurance Providers, Retail Pharmacy), By End Use (Commercial, Federal), And Segment Forecasts, 2023 - 2030
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

美国的药物供给管理(PBM)的市场规模在2030年前将达到9,340亿美元，在2023年到2030年间预计将以8.77％的速度成长。

主要医疗费的增加，药物供给管理(PBM)的偏好的提升，对处方药的需求的增加，促进了市场成长。

本报告提供美国的药物供给管理(PBM)市场相关调查分析，提供市场趋势，市场区隔分析，地区分析，竞争情形等资讯。

目录

第1章 调查范围和目的

第2章 调查手法

第3章 摘要整理

  • 市场预测
  • 市场区隔预测
    • 经营模式
    • 最终用途
      • 竞争的考察

第4章 市场变数，趋势，范围

  • 市场系列预测
    • 母企业的市场预测
    • 附随物/关联的市场预测
  • 市场动态
    • 推动市场要素的分析
    • 阻碍市场要素的分析
  • 渗透与成长预测的製图
  • 商业环境分析工具
    • 波特的五力分析
    • PESTEL分析
  • COVID-19影响:质性分析

第5章 美国的药物供给管理(PBM)市场:经营模式分析

  • 美国的药物供给管理(PBM)的经营模式的市场占有率分析(2022年·2030年)
  • 美国的药物供给管理(PBM)的经营模式市场:市场区隔仪表板
  • 经营模式市场区隔的市场规模与预测，趋势的分析(2017年～2030年)
    • 独立的PBM
    • 健康保险企业
    • 零售药局

第6章 美国的药物供给管理(PBM)市场:最终用途分析

  • 美国的药物供给管理(PBM)的最终用途的市场占有率分析(2022年·2030年)
  • 美国的药物供给管理(PBM)的最终用途市场:市场区隔仪表板
  • 最终用途市场区隔的市场规模与预测，趋势的分析(2017年～2030年)
    • 商业
    • 联邦政府

第7章 竞争分析

  • 最近的趋势及影响分析:各主要打入市场企业
  • 竞争的分类(主要创新者，市场领导者，新兴企业)
  • 企业的市场地位的分析
  • 企业简介
    • CVS HEALTH
    • Elixir Rx Solutions LLC
    • Optum, Inc
    • Cigna
    • Change Healthcare
    • MedImpact
    • Prime Therapeutics LLC
    • HUB International Limited.
    • Anthem
Product Code: GVR-2-68038-826-8

U.S. Pharmacy Benefit Management Market Growth & Trends:

The U.S. pharmacy benefit management market size is expected to reach USD 934.0 billion by 2030, exhibiting a CAGR of 8.77% from 2023 to 2030, according to a new report by Grand View Research, Inc. Increase in healthcare cost, the growing preference for pharmacy benefit management (PBM), and increased demand for prescription drugs are primarily driving the market growth.

PBMs operate with specialty pharmacies to enable beneficiaries to better adherence. These systems provide wide expertise and connections with pharmaceutical companies that can be beneficial to establish drug contracts. Payers find it difficult to establish value-based contracts with pharmaceutical companies. Therefore, payers promote themselves as negotiators and tend to receive considerable discounts on prescription drugs

The vertical integration of pharmacy benefit management (PBM) organizations with health insurance companies is poised to result in increased control of PBMs over distribution systems. This is likely to cause a rise in rebates, ultimately increasing the cost of drug list prices. Moreover, it will result in a monopoly of a certain market player, concentrating sales and revenue generation.

The business of insuring and administering employee benefit programs in the country, especially, health care programs, is heavily regulated by federal and state laws and administrative agencies, such as the Department of Health and Human Services (HHS), State Departments of Insurance, Centers for Medicare & Medicaid Services (CMS), Internal Revenue Services, and Departments of Labor.

The U.S. market for PBM is further fueled by the increasing number of mergers and collaborations between pharmacy benefit management businesses and health insurance providers for bettering the affordability and customization of health insurance policies. Additionally, the launch of enhanced benefit management services, such as disease management, drug utilization programmes, and pharmacy-medical integrated goods, is expected to bode well for the market.

U.S. Pharmacy Benefit Management Market Report Highlights:

  • The standalone segment accounted for the largest revenue share in 2022 owing to the high number of claims processing by PBM. The health insurance segment is expected to witness a significant growth rate during the forecast period
  • Based on end-use, the commercial segment accounted for the largest market share in 2022. The growth of the segment is attributed due to the proliferated usage of private insurance by the public and the increased cost of drugs
  • In February 2022, Southern Scripts, one of the top PBM launched RxCompass, a new solution for mitigating the high cost of prescription drugs for companies and employees in the U.S.
  • In July 2021, major insurers Humana and Anthem announced a partnership with SS&C, a software solutions provider to create a new PBM company named DomaniRx

Table of Contents

Chapter 1 Report Scope and Objectives

  • 1.1 Market Segmentation
  • 1.2 Regional Scope
  • 1.3 Estimates and Forecast Timeline
  • 1.4 Research Objectives
    • 1.4.1 Objective - 1
    • 1.4.2 Objective - 2
    • 1.4.3 Objective - 3

Chapter 2 Methodology

  • 2.1 Research Methodology
  • 2.2 Information Procurement
    • 2.2.1 Purchased Database
    • 2.2.2 GVR's Internal Database
    • 2.2.3 Secondary Sources
    • 2.2.4 Primary Research
    • 2.2.5 Details of Primary Research
  • 2.3 Information or Data Analysis
    • 2.3.1 Data Analysis Models
  • 2.4 Market Formulation & Validation
  • 2.5 Model Details
    • 2.5.1 Commodity Flow Analysis
  • 2.6 List of Secondary Sources
  • 2.7 List of Abbreviations

Chapter 3 Executive Summary

  • 3.1 Market Outlook
  • 3.2 Segment Outlook
    • 3.2.1 Business Model
    • 3.2.2 End - use
      • 3.3Competitive Insights

Chapter 4 Market Variables, Trends & Scope

  • 4.1 Market Lineage outlook
    • 4.1.1 Parent market outlook
    • 4.1.2 Ancillary/related market outlook
  • 4.2 Market Dynamics
    • 4.2.1 Market driver analysis
      • 4.2.1.1 Vertical integration of key market players
      • 4.2.1.2 Introduction of improved health benefit plans
      • 4.2.1.3 Growing prevalence of chronic diseases in the U.S.
    • 4.2.2 Market restraint analysis
      • 4.2.2.1 Stringent regulations to cut back rebates
  • 4.3 Penetration & Growth Prospect Mapping
  • 4.4 Business Environment Analysis Tools
    • 4.4.1 Porter's Five Forces analysis
      • 4.4.1.1 Competitive rivalry
      • 4.4.1.2 Threat of new entrants
      • 4.4.1.3 Bargaining power of buyers
      • 4.4.1.4 Bargaining power of suppliers
      • 4.4.1.5 Threat of substitutes
    • 4.4.2 PESTEL Analysis
      • 4.4.2.1 Political landscape
      • 4.4.2.2 Economic and social landscape
      • 4.4.2.3 Technological landscape
  • 4.3 Impact of COVID - 19: Qualitative Analysis

Chapter 5 U.S. Pharmacy Benefit Management Market: Business Model Analysis

  • 5.1 U.S. Pharmacy Benefit Management Business Model Market Share Analysis, 2022 & 2030
  • 5.2 U.S. Pharmacy Benefit Management Business Model Market: Segment Dashboard
  • 5.3 Market Size & Forecasts and Trend Analyses, 2017 to 2030 for the Business Model Segment
    • 5.3.1 Standalone PBM
      • 5.3.1.1 Standalone PBM market, 2017 - 2030 (USD Billion)
    • 5.3.2 Health Insurance Providers
      • 5.3.2.1 Health insurance providers market, 2017 - 2030 (USD Billion)
    • 5.3.3 Retail Pharmacy
      • 5.3.3.1 Retail pharmacy market, 2017 - 2030 (USD Billion)

Chapter 6 U.S. Pharmacy Benefit Management Market: End - use Analysis

  • 6.1 U.S. Pharmacy Benefit Management End - use Market Share Analysis, 2022 & 2030
  • 6.2 U.S. Pharmacy Benefit Management End - use Market: Segment Dashboard
  • 6.3 Market Size & Forecasts and Trend Analyses, 2017 to 2030 for the End - use Segment
    • 6.3.1 Commercial
      • 6.3.1.1 Commercial market, 2017 - 2030 (USD Billion)
    • 6.3.2 Federal
      • 6.3.2.1 Federal market, 2017 - 2030 (USD Billion)

Chapter 7 Competitive Analysis

  • 7.1 Recent Developments & Impact Analysis, by Key Market Participants
  • 7.2 Competition Categorization (Key innovators, Market leaders, Emerging Players
  • 7.3 Company Market Position Analysis
  • 7.4 Company Profiles
    • 7.4.1 CVS HEALTH
      • 7.4.1.1 Company overview
      • 7.4.1.2 Financial performance
      • 7.4.1.3 Service benchmarking
      • 7.4.1.4 Strategic initiatives
    • 7.4.2 Elixir Rx Solutions LLC
      • 7.4.2.1 Company overview
      • 7.4.2.2 Service benchmarking
      • 7.4.2.3 Strategic initiatives
    • 7.4.3 Optum, Inc
      • 7.4.3.1 Company overview
      • 7.4.3.2 Financial performance
      • 7.4.3.2 Service benchmarking
      • 7.4.3.3 Strategic initiatives
    • 7.4.4 Cigna
      • 7.4.4.1 Company overview
      • 7.4.4.2 Financial performance
      • 7.4.4.2 Service benchmarking
      • 7.4.4.3 Strategic initiatives
    • 7.4.5 Change Healthcare
      • 7.4.5.1 Company overview
      • 7.4.5.2 Service benchmarking
      • 7.4.5.3 Strategic initiatives
    • 7.4.6 MedImpact
      • 7.4.6.1 Company overview
      • 7.4.6.2 Financial performance
      • 7.4.6.3 Service benchmarking
      • 7.4.6.4 Strategic initiatives
    • 7.4.7 Prime Therapeutics LLC
      • 7.4.7.1 Company overview
      • 7.4.7.2 Service benchmarking
      • 7.4.7.3 Strategic initiatives
    • 7.4.8 HUB International Limited.
      • 7.4.8.1 Company overview
      • 7.4.8.2 Service benchmarking
      • 7.4.8.3 Strategic initiatives
    • 7.4.9 Anthem
      • 7.4.9.1 Company overview
      • 7.4.9.2 Financial performance
      • 7.4.9.3 Service benchmarking
      • 7.4.9.4 Strategic initiatives  

List of Tables

  • TABLE 1 List of secondary sources
  • TABLE 2 List of abbreviations
  • TABLE 3 U.S. U.S. pharmacy benefit management market, by business model, 2017 - 2030 (USD Billion)
  • TABLE 4 U.S. U.S. pharmacy benefit management market, by end-use, 2017 - 2030 (USD Billion)

List of Figures

  • FIG. 1 Market research process
  • FIG. 2 Information procurement
  • FIG. 3 Primary research pattern
  • FIG. 4 Market research approaches
  • FIG. 5 Value chain based sizing & forecasting
  • FIG. 6 QFD modeling for market share assessment
  • FIG. 7 Market formulation & validation
  • FIG. 8 Market outlook
  • FIG. 9 Pharmacy benefit management market segmentation
  • FIG. 10 Market trends & outlook
  • FIG. 11 Market driver relevance analysis (Current & future impact)
  • FIG. 12 Market restraint relevance analysis (Current & future impact)
  • FIG. 13 Penetration & growth prospect mapping
  • FIG. 14 U.S. pharmacy benefit management business model market share analysis, 2022 & 2030
  • FIG. 15 U.S. pharmacy benefit management business model market: Segment dashboard
  • FIG. 16 Standalone PBM market, 2017 - 2030 (USD Billion)
  • FIG. 17 Health insurance providers market, 2017 - 2030 (USD Billion)
  • FIG. 18 Retail pharmacy market, 2017- 2030 (USD Billion)
  • FIG. 19 U.S. pharmacy benefit management market end-use movement analysis, 2022 & 2030
  • FIG. 20 U.S. pharmacy benefit management end-use market: Segment dashboard
  • FIG. 21 Commercial market, 2017 - 2030 (USD Billion)
  • FIG. 22 Federal market, 2017- 2030 (USD Billion)
  • FIG. 23 Recent developments & impact analysis, by key market participants
  • FIG. 24 Strategy framework
  • FIG. 25 Competition Categorization
  • FIG. 26 Company market position analysis